A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac

NCT04034290 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
224
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Collaborators